UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatobiliary and Pancreatic: Spontaneous intrahepatic hemorrhage from peliosis hepatis-An uncommon complication of a rare liver disorder

Journal of gastroenterology and hepatology, 2014-10, Vol.29 (10), p.1754-1754

2014

Volltextzugriff (PDF)

Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Hepatology (Baltimore, Md.), 2011-11, Vol.54 (5), p.1591-1599

2011

Volltextzugriff (PDF)

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis

Journal of viral hepatitis, 2012-10, Vol.19 (10), p.732-743

2012

Volltextzugriff (PDF)

Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay

Clinical and Vaccine Immunology, 2011-11, Vol.18 (11), p.1943-1950

2011

Volltextzugriff (PDF)

Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients

Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (9), p.1306-1316

2018

Volltextzugriff (PDF)

Pharmacokinetics, safety and antiviral activity of CMX157, a novel prodrug of tenofovir, administered as ascending multiple doses to healthy volunteers and Hepatitis B virus-infected subjects

Journal of hepatology, 2017, Vol.66 (1), p.S24-S25

2017

Volltextzugriff (PDF)

P407 HBeAg INDEX AND HBVDNA REDUCTION CAN PREDICT LONG TERM RESPONSE OF CHRONIC HEPATITIS B, HBeAg POSITIVE PATIENTS TREATED WITH PEGINTERFERON ALPHA-2a: A THREE-YEAR FOLLOW-UP

Journal of hepatology, 2014-04, Vol.60 (1), p.S203-S204

2014

Volltextzugriff (PDF)

Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial

Journal of hepatology, 2017, Vol.66 (1), p.S529-S529

2017

Volltextzugriff (PDF)

HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study

Journal of hepatology, 2016, Vol.64 (2), p.S604-S604

2016

Volltextzugriff (PDF)

1208 BIT225, AN HCV-P7 INHIBITOR, WITH ENHANCED ANTI-HCV ACTIVITY IN COMBINATION WITH PEGYLATED INTERFERONalfa- 2b AND RIBAVIRIN IN HCV GENOTYPE-1 TREATMENT NAÏVE SUBJECTS: PHARMACOKINETIC AND RESISTANCE STUDIES

Journal of hepatology, 2013-04, Vol.58, p.S491-S491

2013

Volltextzugriff (PDF)

Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand

Value in health, 2014-11, Vol.17 (7), p.A677-A677

2014

Volltextzugriff (PDF)

69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS

Journal of hepatology, 2011-03, Vol.54, p.S31-S31

2011

Volltextzugriff (PDF)

1142 INCREASED BONE MINERAL DENSITY IN CHRONIC HEPATITIS C PATIENTS AFTER TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN COMBINATION

Journal of hepatology, 2011-03, Vol.54, p.S451-S451

2011

Volltextzugriff (PDF)

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Journal of viral hepatitis, 2013-04, Vol.20 (4), p.e115-e123

2013

Volltextzugriff (PDF)

EE353 Cost-Effectiveness of Ravidasvir Plus Sofosbuvir Compared to the Standard of Care in Patients with Chronic Hepatitis C in the Thai Healthcare Setting

Value in health, 2023-06, Vol.26 (6), p.S124-S124

2023

Volltextzugriff (PDF)

539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S214-S214

2012

Volltextzugriff (PDF)

738 HIGHEST RATES OF RESPONSE AT WEEK 72 OF THE NEPTUNE STUDY ARE ACHIEVED WITH PEGINTERFERON ALFA-2A 180 μG FOR 48 WEEKS

Journal of hepatology, 2011-03, Vol.54, p.S296-S296

2011

Volltextzugriff (PDF)

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Journal of viral hepatitis, 2012-09, Vol.19 (9), p.623-634

2012

Volltextzugriff (PDF)

424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

Journal of hepatology, 2011-03, Vol.54, p.S171-S172

2011

Volltextzugriff (PDF)

A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology

Case Reports in Hepatology, 2019, Vol.2019 (2019), p.1-4

2019

Volltextzugriff (PDF)

Liver Dysfunction in Hyperthyroidism

Hepatic medicine: evidence and research, 2024-11, Vol.16, p.81-89

2024

Volltextzugriff (PDF)

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

Journal of hepatology, 2010, Vol.52, p.S390-S391

2010

Volltextzugriff (PDF)

180 ORAL L-ORNITHINE-L-ASPARTATE (LOLA) FOR PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY TREATED WITH LACTULOSE; A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL

Journal of hepatology, 2010, Vol.52, p.S78-S78

2010

Volltextzugriff (PDF)

7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE

Journal of hepatology, 2010, Vol.52, p.S4-S4

2010

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(233)

Publikationsform

Artikel
(242)
Buchkapitel
(1)

Sprache

Englisch
(241)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Hepatobiliary and Pancreatic: Spontaneous intrahepatic hemorrhage from peliosis hepatis-An uncommon complication of a rare liver disorder

Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis

Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay

Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients

Pharmacokinetics, safety and antiviral activity of CMX157, a novel prodrug of tenofovir, administered as ascending multiple doses to healthy volunteers and Hepatitis B virus-infected subjects

P407 HBeAg INDEX AND HBVDNA REDUCTION CAN PREDICT LONG TERM RESPONSE OF CHRONIC HEPATITIS B, HBeAg POSITIVE PATIENTS TREATED WITH PEGINTERFERON ALPHA-2a: A THREE-YEAR FOLLOW-UP

Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial

HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study

1208 BIT225, AN HCV-P7 INHIBITOR, WITH ENHANCED ANTI-HCV ACTIVITY IN COMBINATION WITH PEGYLATED INTERFERONalfa- 2b AND RIBAVIRIN IN HCV GENOTYPE-1 TREATMENT NAÏVE SUBJECTS: PHARMACOKINETIC AND RESISTANCE STUDIES

Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand

P0612 : Interferon-gamma-inducible protein 10 promoter polymorphism related with end-of-treatment HBsAg levels and had complementary role in prediction of sustained virologic response to peginterferon in HBeAg-negative chronic hepatitis B: Multicenter study

69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS

1142 INCREASED BONE MINERAL DENSITY IN CHRONIC HEPATITIS C PATIENTS AFTER TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN COMBINATION

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

EE353 Cost-Effectiveness of Ravidasvir Plus Sofosbuvir Compared to the Standard of Care in Patients with Chronic Hepatitis C in the Thai Healthcare Setting

539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

738 HIGHEST RATES OF RESPONSE AT WEEK 72 OF THE NEPTUNE STUDY ARE ACHIEVED WITH PEGINTERFERON ALFA-2A 180 μG FOR 48 WEEKS

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology

Liver Dysfunction in Hyperthyroidism

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

180 ORAL L-ORNITHINE-L-ASPARTATE (LOLA) FOR PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY TREATED WITH LACTULOSE; A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL

7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE

Suchergebnisse filtern